This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Warner Chilcott's CEO Discusses Q1 2012 Results - Earnings Call Transcript

We were disappointed to receive a warning letter on our Fajardo manufacturing facility earlier this year in March. We are working to address the items outlined in the warning letter and aim to get those resolved as quickly as possible.

Rather than speculate on timing, I will reassure you the revolution is a top priority for us; one we take seriously and are highly focused on.

As most of you probably have seen, early this week we learned the Judge’s decision at the Doryx trial. The Judge determined that our Doryx patent is valid, but not infringed by either Mylan or Impax. And consequently, we learned that Mylan entered the market with a generic equivalent of our Doryx 150.

Paul will discuss how this impacts our guidance. You should understand, we are committed to the derm space and plan to continue sales and marketing, R&D and business development efforts in this area.

Speaking of business development, we issued a press release earlier this week disclosing our preliminary discussions with potential offers as well as our valuation of a broad range of strategic alternatives to enhance shareholder value. We will not, repeat, not comment further today on this topic.

With that, let me turn it over to Paul for some thoughts about our first quarter financial performance.

Paul Herendeen

Yes, thanks, Roger. As Roger mentioned, but I do want to reiterate, 2012’s off to a strong start with several of our key ramp brands delivering revenue growth in the quarter, including Estrace Cream, Loestrin franchise, Asacol and Atelvia. The performance of these key brands, coupled with favorable gross margins in the period and our success in gaining additional leverage over our operating costs, allowed us to deliver a solid growth in adjusted cash on our income in the quarter; up 9% compared with Q1 of last year.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SYM TRADE IT LAST %CHG
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%

Markets

Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs